What additional health concern might arise for a client undergoing antitubercular treatment?

Clients undergoing antitubercular treatment are at risk of developing hepatotoxicity, which refers to liver damage caused by medications. Antitubercular drugs, especially isoniazid, rifampicin, and pyrazinamide, have known side effects that can strain liver function. Monitoring liver health becomes critical during treatment, as the liver is vital for metabolizing these drugs. Symptoms of hepatotoxicity can include jaundice, fatigue, and elevated liver enzymes, which necessitate close observation and possible intervention if liver function is compromised.

Other health concerns related to antitubercular treatment, such as hypertension, respiratory complications, or neuropathy, are less commonly associated with these specific medications. While they might be relevant in different contexts or patient populations, the prominent and direct link to antitubercular therapy is notably the risk of liver damage, making hepatotoxicity the most pertinent concern in this scenario.